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Background/Aim. The Chronic obstructive pulmonary 
disease (COPD) Assessment Test (CAT) is a simple and 
reliable tool designed to measure overall COPD related 
health status and complement physician assessment in rou-
tine clinical practice. Objective of this study was to evaluate 
the validity of the Serbian version of CAT. Methods. Study 
included 140 outpatients in the stable COPD, recruited 
from two centres: Clinic for Pulmonology, Clinical Center 
of Serbia, Belgrade, and Institute for Pulmonary Diseases of 
Vojvodina, Sremska Kamenica. All patients completed 
pulmonary function testing – spirometry, the CAT and the 
modified Medical Research Council (mMRC) dyspnea scale 
at baseline visit. The CAT test-retest reliability was tested in 
20 patients by the same investigator (physician). Results. 
We demonstrated that Serbian version of CAT had high 
internal consistency with Cronbach’s alpha 0.88. Test-retest 
analysis showed good correlation between CAT scores in 
two time points (Spearman’s ρ = 0.681, p < 0.01). In our 
study the CAT correlated moderately to mMRC scale (ρ = 
+0.57), weakly to FEV1 (ρ -0.214), was positively related to 
number of exacerbations, but did not showed exact 
regularity with change in the Global Initiative for Chronic 
Obstructive lung disease (GOLD) stage. Conclusion. The 
Serbian version of CAT is a reliable, simple and easy-to-use 
tool that can be used in everyday clinical practice to assess 
the health status of COPD patients in Serbia. 
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Uvod/Cilj. Upitnik za procenu hronične opstruktivne 
bolesti pluća (HOBP) (engl. COPD Assessment Test - CAT) je 
jednostavan i pouzdan test namenjen za merenje ukupnog 
zdravstvenog stanja bolesnika sa HOBP i koristan je za upo-
trebu u svakodnevnoj kliničkoj praksi. Cilj ovog istraživanja 
bio je da se proceni validnost i opravdanost primene srpske 
verzije CAT. Metode. U studiji je učestvovalo 140 boles-
nika u stabilnom stanju HOBP, ispitivanih u ambulantnim 
uslovima na Klinici za pulmologiju, Kliničkog centra Srbije 
u Beogradu i Institutu za plućne bolesti Vojvodine u 
Sremskoj Kamenici. Tokom prvog pregleda bolesnicima je 
učinjeno ispitivanje plućne funkcije (spirometrija), popunili 
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su CAT upitnik i mMMR (modified Medical Research Council) 
skalu za procenu stepena dispneje. Pouzdanost CAT test-
retesta je ispitivana kod 20 bolesnika od strane istog 
istraživača. Rezultati. Pokazali smo da srpska verzija CAT 
ima visoku internu konzistentnost sa Cronbach-ovim alfa 
0.88. Test-retest analiza pokazala je dobru korelaciju između 
CAT rezultata u dve vremenske tačke (Spearmanov 
r = 0,681; p < 0,01). CAT je umereno korelirao sa mMRC 
skalom (r = + 0,57), blago sa forsiranim ekspiratornim 
volumenom u prvoj sekundi (FEV1), (r -0,214), uz pozitivnu 
korelaciju sa ukupnim brojem pogoršanja HOBP, ali bez 
jasne regularnosti sa promenom GOLD (Global Initiative for 
Chronic Obstructive Lung Disease) stadijuma. Zaključak. 
Srpska verzija CAT je pokazala visoku internu konzistent-
nost i test-retest pouzdanost. Ona predstavlja pouzdano, 
jednostavno i lako sredstvo za upotrebu koje se može koris-
titi u svakodnevnoj kliničkoj praksi za procenu zdravstve-
nog stanja kod bolesnika sa HOBP u Srbiji. 
 
Ključne reči: 
pluća, opstruktivne bolesti; hronične; ankete i upitnici; 
srbija; komorbiditet; ekspiratorni volumen, forsirani. 
 
Introduction 
The Global initiative for Chronic Obstructive Lung 
Disease (GOLD) strategy document defined chronic 
obstructive pulmonary disease (COPD) as a preventable and 
treatable disease, with persistent respiratory symptoms and 
airflow limitation 1. Smoking is the main risk factor for 
disease development along with environmental exposures to 
biomass fuels and air pollution. Also, individual predispo-
sing factors such as genetic abnormalities, abnormal lung 
development, and accelerated aging contribute to COPD de-
veloping. A course of the disease is often progressive and 
associated with significant comorbidities which increase its 
morbidity and mortality. 
COPD is one of the most common diseases with a 
global prevalence of 11.7% 2. Prevalence of chronic bron-
chitis symptoms in Belgrade, Serbia was 21.6% 3. Also, in 
the other study COPD diagnosis, confirmed by the pulmo-
nologist, was in 21.9% of the patients and newly diagnosed 
COPD in 10.9% of the patients 4. 
COPD is one of the fastest growing causes of death and 
it is expected to be the 3rd cause of mortality by 2020 
worldwide 1. The disease may cause disability and the 
quality of life is one of the treatment goals. Health status 
assessment in COPD patients is a routine in clinical research 
studies with comprehensive but time-consuming  
tools such as the St. George’s Respiratory Questionnaire 
(SGRQ), the Chronic Respiratory Disease Questionnaire 
(CRQ) and the COPD Clinical Questionnaire (CCQ) 5–7. 
The COPD Assessment Test (CAT) is a simple and 
reliable tool designed to measure overall COPD-related 
health status and complement physician assessment in rou-
tine clinical practice 8. It is a short, self-administered, eight-
item questionnaire that includes symptoms, limitation of 
daily activity, sleep quality and energy, providing a single 
score. It is easy to complete by the patient and interpret by 
the clinician. The CAT was developed and validated inter-
nationally, in the Europe and United States, and has been 
translated into many languages worldwide 9. 
The GOLD recognized the importance of the CAT in 
the multidimensional system of assessment of the disease 
severity and selection of pharmacological treatment, as well 
as monitoring of the disease. 
The aim of this cross-sectional study was to evaluate 
the validity of the Serbian version of the CAT. 
Methods 
The study was conducted in accordance with the Good 
Clinical Practice as outlined in the Declaration of Helsinki 
2000. All necessary approvals for the trial were obtained 
from respective institutional review and ethical boards. 
Study population and design 
The study was independently conducted, and 140 
patients were recruited from two Serbian centres: the Clinic 
for Pulmonology, Clinical Center of Serbia, Belgrade (98 
subjects) and the Institute for Pulmonary Diseases of 
Vojvodina, Sremska Kamenica (42 subjects) from May 2017 
to January 2018. 
They were outpatients in the stable stage of COPD, 
older than 40 years of age, smokers or ex-smokers. COPD 
was diagnosed according to the GOLD criteria 1, not earlier 
than 6 months prior to the study. Inclusion criteria were 
COPD stable stage and written informed consent. 
Exclusion criteria were: active respiratory disorder other 
than COPD, immunosuppression, or subjects unable to 
complete the questionnaires. Stable COPD is defined as no 
change in respiratory state in duration of 4 weeks that 
requires no change in therapy, or systemic steroids and/or 
antibiotics use. Patient characteristics included demo-
graphic information, smoking, COPD and exacerbations 
history, therapy and comorbidities (cardiovascular diseases 
– heart failure, arterial hypertension, ischemic heart 
disease, arrhythmia, peripheral artery diseases, osteo-
porosis, depression, diabetes, and gastroesophageal reflux). 
At the baseline visit, the patient’s breathlessness was 
assessed using the Modified Medical Research Council 
(mMRC) dyspnea scale, and spirometry test was performed 
according to the American Thoracic Society/European 
Respiratory Society (ATS/ERS) spirometry guidelines 10. 
Patients are further classified according to the airflow 
limitation severity based on post-bronchodilator forced 
expiratory volume in the first second (FEV1) in patients 
with FEV1/forced volume vital capacity (FVC) < 0.70 to 
the GOLD stages: mild – GOLD 1 (FEV1 ≥ 80%), moderate 
Page 296 VOJNOSANITETSKI PREGLED Vol. 77, No 3 
Milenković B, et al. Vojnosanit Pregl 2020; 77(3): 294–299. 
– GOLD 2 (FEV1 50–79%), severe –GOLD 3 (FEV1 30–
49%), and very severe –GOLD 4 (FEV1 < 30%). The CAT 
was administered to all the patients at the baseline visit by 
the same investigator (physician). The CAT was again 
administered to twenty patients by the same investigator, at 
the second visit, 14 days after the first one. 
Questionnaire 
The CAT is a disease-specific questionnaire assessing 
health status in individuals with COPD. The CAT and CAT 
logo is a trade mark of GlaxoSmithKline group of companies. 
The CAT can be freely used. For this study we used already 
available Serbian translation of CAT written in consistent and 
understandable language, so there was no need for back-
translation analysis. The CAT consists of the following eight 
items, each formatted as a minimum and maximum score of 0 to 
5, respectively: cough, phlegm, chest tightness, and 
breathlessness going up hills/stairs, activity limitations at home, 
confidence leaving home, sleep, and energy. Individual item 
scores are summarized to provide a total CAT score that can 
range from 0 (floor) to 40 (ceiling). 
Statistical analysis 
Internal consistency of the CAT questionnaire was tested 
by Cronbach’s α coefficient analysis. Correlation analysis 
between the CAT score and mMRC dyspnea scale was 
performed, so as correlation between CAT score and pulmonary 
function measures [FEV1 (L, %), FVC (L, %), FEV1/FVC]. 
Test-retest analysis obtained as correlation analysis between 
CAT scores in two time points, was performed by the same 
investigators (physicians). Differences between continuous 
variables were tested by using Student’s t test, ANOVA for 
variables with normal distribution, or Mann-Whitney U test or 
Kruskal-Wallis nonparametric ANOVA for parameters which 
distribution deviated from normal Gaussian distribution pattern. 
Differences in frequency of categorical variables were tested 
with χ2 test. Correlation analysis performed by using 
Spearman’s nonparametric correlation methods. All differences 
were set at 0.05 alpha. 
Results 
From May 2017 to January 2018, 140 patients with COPD 
completed the CAT questionnaire and mMRC dyspnea scale, 
and 20 patients completed the CAT test in two time points, 
performed by the same investigator (physician). General 
characteristic of subjects (mean age 64.4 ± 9.3 years; 84 men 
and 56 women) are summarized in Table 1. The majority of 
subject were ex-smokers (n = 82; 60%), and the rest were active 
smokers (n = 58; 41%). There were no subjects who never 
smoked. The mean body mass index (BMI) was 26.6 ± 5.4 
kg/m2. Average FEV1 was 47.6 ± 19.1% which indicated 
moderate to severe airflow limitation. Average mMRC score 
was 1.93 ± 1.11 and average CAT was 19.5 ± 8.9, which 
implied that patients had more symptoms and more pronounced 
breathlessness (Table 1). 
The Cronbach’s α was 0.887 for the CAT test. Neither 
Cronbach’s α item deleted value was not larger than basic 
value of 0.887, so we concluded that all questions are 
consistent with the questionnaire topic. We found 
significant positive correlation between the CAT score and 
mMRC score (ρ = +0.570; p < 0.001). The CAT score 
showed weak but significant negative correlation with FVC 
(L): ρ = - 0.274; p < 0.01) and FEV1 (L): (-0.214; p < 0.05), 
but did not correlate with any other pulmonary function 
measure. Test-retest analysis showed good correlation 
between CAT scores in two time points (Spearman’s ρ = 
0.681; p < 0.01). 
 
Table 1 
General anthropometric, demographic, pulmonary 
function data and average modified Medical Research 
Council Dyspnea Scale (mMRC) and Chronic 
Obstructive Pulmonary Disease Assessment Test  
(CAT) score in the study population 
Parameter Values 
Age (years), mean ± SD 64.4 ± 9.3 




BMI (kg/m2), mean ± SD 26.6 ± 5.4 
Post-BD FEV1 (L), mean ± SD 1.27 ± 0.59 
Post-BD FEV1 (%), mean ± SD 47.6 ± 19.1 
Post-BD FVC (L), mean ± SD 2.73 ± 0.92 
Post-BD FVC (%), mean ± SD 81.9 ± 21.0 
Post-BD FEV1/FVC, mean ± SD 46.2 ± 12.3 
mMRC score, mean ± SD 1.93 ± 1.11 
Total CAT score, mean ± SD 19.5 ± 8.9 
BMI – body mass index; BD-FEV1 – bronchodilator-forced 
expiratory volume in the first second; BD-FVC – 
bronchodilator-forced volume vital capacity; SD – standard 
deviation. 
 
Next, patients were classified according to the GOLD 
stage (I–IV). In the GOLD stage groups we compared 
different general, anthropometric, clinical and pulmonary 
function parameters, exacerbation status and maintenance 
therapy (Table 2). There was no difference in distribution of 
ex-smokers and smokers, and cumulative smoking status 
expressed in pack/years among GOLD I–IV groups. Patients 
with longer disease duration tended to be in higher GOLD 
stage groups, but there was no significant difference. 
Average COPD duration was from 4 years in the GOLD I 
group to 8.5 years in the GOLD IV group. Patients with 
higher GOLD stage had significantly more acute 
exacerbation episodes (GOLD III and IV groups compared to 
II and I), and also higher number of exacerbations requiring 
hospitalization (especially the GOLD IV group compared to 
other three groups). Regarding maintenance therapy higher 
percentage of patients used long acting muscarinic 
antagonists (LAMA) and inhaled glucocorticoid (ICS)/long 
acting bronchidilators (LABA) in higher GOLD stage 
groups. The mMRC breathlessness score was highest in the 
GOLD IV group compared to other three GOLD groups. On 
the contrary, the CAT total score did not show exact 
regularity with the GOLD stage change (Table 2). 
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Table 2 
Demographic, clinical and functional characteristics, exacerbations and therapy  
of the study population related to the GOLD stadium classification 
Parameter 
GOLD I 
(n = 10) 
GOLD II 
(n = 48) 
GOLD III 
(n = 53) 
GOLD IV 
(n = 30) 
p 
Age, years 63.4 ± 6.4 65.2 ± 9.8 65.7 ± 8.4 58.8 ± 9.3c 0.041 











BMI (kg/m2), mean ± SD 30.0 ± 6.7 27.7 ± 5.5 26.8 ± 4.7 23.2 ± 4.9a 0.038 
Pack years, mean ± SD 42.1 ± 20.0 33.8 ± 17.4 34.6 ± 17.3 33.7 ± 20.5 0.725 


























1 (0–2)a,b 0.006 
FEV1 (%), mean ± SD 86.6 ± 9.9 60.8 ± 8.2aaa 39.7 ± 5.8aaa,bbb 24.4 ± 3.4aaa,bbb,ccc < 0.001 
FEV1 (L), mean ± SD 2.38 ± 0.63 1.60 ± 0.47aaa 1.08 ± 0.29aaa,bbb 0.69 ±  0.17aaa,bbb,ccc < 0.001 
FVC (%), mean ± SD 107.6 ± 11.1 94.3 ± 13.5 78.6 ± 17.3aaa,bbb 59.4 ± 15.4aaa,bbb,ccc < 0.001 
FVC (L), mean ± SD 




FEV1/FVC, mean ± SD 65.1 ± 8.5 53.2 ± 8.9aaa 42.9 ± 8.6aaa,bbb 34.4 ± 9.4aaa,bbb,ccc < 0.001 
LAMA therapy,  n (%) 5 (71) 31 (93.9) 37 (97.4) 20 (100) 0.024 
LABA therapy, n (%) 1 (14.3) 6 (18.2) 7 (18.4) 4 (20.0) 0.852 
ISC/LABA therapy, n (%) 3 (42.9) 17 (51.5) 30 (78.9) 16 (80.0) 0.025 
mMRC dyspnea score, mean ± SD 1.00 ± 0.82 1.70 ± 1.10 2.11 ± 1.08 2.50 ± 0.95aa,b     0.009 









GOLD – Global initiative for Chronic Obstructive Lung Disease; BMI – body mass index; COPD – chronic obstructive 
pulmonary disease; FEV1 – forced expiratory volume in the first second; FVC – forced volume vital capacity; LAMA – long 
acting muscarinic antagonist; LABA – long acting bronchodilators; ICS – inhaled glucocorticoid; mMRC – modified Medical 
research council; CAT – COPD assessment test. 
*parameters with non-normal distribution presented as median (25th–75th percentile) values; p from parametric (ANOVA) 
or from non-parametric (Kruskal-Wallis) tests; a, b, c letters indicate significant difference compared to the GOLD I, the 
GOLD II and the GOLD III group, respectively (one letter –  p < 0.05,  two letters –  p < 0.01, three letters – p < 0.001). 
 
 
Relation between the CAT score and presence of co-
morbidities, all and cardiovascular, and number of exacerba-
tion/year are summarized in Table 3. 
 
Table 3 




mean ± SD p 
Comorbidities    
   none 70 (50) 17.2 ± 8.5 
   At least one 70 (50) 20.1 ± 10.2 
0.184 
CVB comorbidity    
   none 59 (42) 18.2 ± 9.0 
   At least one 81 (58) 16.9 ± 8.7 
0.539 
Exacerbations    
   none 26 (18) 12.0 ± 6.4 
   1          33 (24) 17.3 ± 10.2 
   ≥ 2        81 (58) 20.0 ± 8.3aa 
0.003 
CAT – Chronic Obstructive Pulmonary Disease Assessment 
Test; CVB – cerebrovascular burden. 
p from ANOVA (aa p <  0.001 vs. group without exacerbation). 
There was no significant difference in the CAT score 
between subjects with or without investigated comorbidities. 
On the contrary, an increase in exacerbation number was 
related consistently with higher CAT score (p < 0.01), so 
patients with 2 or more exacerbations during one year had 
significantly higher CAT score (Table 3). We also compared 
CAT scores between body mass index (BMI subgroups, but 
neither any regularity nor statistical significance were found. 
Discussion 
The study demonstrated good internal consistency and 
reliability of the CAT score in a population of COPD 
patients in Serbia. The CAT correlated moderately with the 
mMRC scale, did not differ significantly across spirometric 
GOLD stages and was higher in patients who experienced 
frequent exacerbations. 
The CAT is a short (8-item), self-administered ques-
tionnaire developed by Jones et al. 5, 8 for the purpose of 
measuring health status of patients with COPD. It was 
derived from the data from three international observational 
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prospective studies including 1,503 COPD patients from 
Belgium, France, Germany, the Netherlands, Spain and the 
USA following rigorous methodological approach and was 
subsequently validated in the subgroup of patients from the 
USA. This study showed excellent consistency of the 
questionnaire with the Cronbach’s alpha of 0.88 and a good 
reliability 8. Soon after it was developed, the CAT was 
incorporated into the GOLD guidelines as a part of a 
multidimensional assessment of COPD patients. Currently, 
the CAT is the preferred method for symptom assessment 
over traditionally used the unidimensional mMRC scale that 
measures only breathlessness, as it is more comprehensive 
(GOLD). Also, the CAT demonstrated a very good cor-
relation with the SGRQ that is commonly used to access the 
impact of COPD on health status in clinical trials but is too 
complex for use in a busy every day practice 8. 
Since the CAT questionnaire was developed and 
validated in English language it is possible that cultural, 
social, and linguistic differences may affect its performance 
in other populations. Hence, after its publication in 2009, the 
CAT has been translated and validated in various countries 
including Japan 11, Indonesia, Korea, Vietnam 12, Thailand 13, 
Brazil 14, Turkey 15, Iran 16 and Arabic speaking countries 17. 
To our knowledge our study was the first that validated the 
use of the CAT in Serbian language. 
We demonstrated that the Serbian version of CAT has 
high internal consistency with Cronbach’s alpha 0.88 that is 
identical to original version of CAT 8 and comparable to 
other validation studies in which Cronbach’s alpha ranged 
from 0.73 to 0.98 thus exhibiting high item correlation 16, 18. 
The demographic characteristics of our study population 
were similar to derivation cohort 8 with 60% men, mean age 
64 years, but our patients had more severe airway obstruction 
(mean FEV1 47.6 ± 19.1% predicted compared to 52.3 ± 
18.9% predicted in the US and 57.8 ± 19.9% predicted in the 
EU cohort). The mean values of the CAT score was 19.5 ± 
8.9 indicating that patients had high symptom burden and 
pronounced breathlessness which is comparable to CAT 
scores in studies from Belgium, France, Germany, US, 
Portugal and Asian population 12, 14, 19. 
Test-retest reproducibility measured at two time points 
in our study was good (Spearman’s ρ = 0.681) and consistent 
with other validation studies. When compared to other 
important functional and physiological variables, the CAT 
correlated moderately to the mMRC scale (ρ = +0.57) and 
weakly to FEV1 (ρ -0.214). This is in line with previous 
studies in which the correlation between the CAT and 
mMRC scale (ρ = 0.29–0.61) and FEV1 (ρ = -0.56–-0.23) 
was found to be moderate at best 18. Although in our study 
more severe COPD patients (the groups 3 and 4) had higher 
CAT scores the difference between the COPD groups was 
not significant. By contrast, a cross-sectional European 
study 19 showed a constant increase of the CAT score across 
COPD stages with 3 points difference between the classes. 
In our study, the CAT was positively related to number 
of exacerbations. Frequent exacerbators (≥ 2 exacerbations) 
had higher CAT scores compared to non exacerbators (20.0 
± 8.3 vs. 12.0 ± 6.4, respectively). Previous studies have also 
demonstrated that infrequent exacerbators have lower values 
of the CAT score compared to patients with ≥ 2 
exacerbations 20, 21. In addition, CAT values are shown to be 
higher in patients experiencing exacerbation compared to 
stable patients with a mean difference of 4.7 units between 
the groups 8, 19, 22. 
We found no difference in CAT scores in patients with 
and without comorbidities. This is consistent with study by 
Kwon et al. 12 in Asian population but differs from large 
European study where presence of 3 or more comorbidities 
has been associated with higher CAT scores 19. This may be 
due to a difference in sample size, as study by Jones et al. 12 
included significantly higher number of patients that allowed 
subgroup analysis. Similarly to aforementioned studies we 
found no difference in CAT scores between patients with and 
without cardiovascular disease. Also, in contrast to previous 
data that showed that patients with lower BMI have higher 
CAT scores 12 in our study the CAT score did not differ 
across BMI groups. 
Our study has several limitations. First, the study included 
COPD patients from two academic pulmonary hospitals that are 
not necessarily generalizable to all COPD patients in Serbia. 
Second, although number of patients is comparable to other 
questionnaire validation studies, our study was likely 
underpowered to detect between group differences which may 
explain the observed dissimilarities (such as non-significant 
differences in CAT values across GOLD stages and BMI 
groups) when compared to larger studies. Nevertheless, this is 
the first study to validate the CAT in Serbian language that 
confirmed its reliability and consistency. 
Conclusion 
The Serbian version of the CAT is an easy to administer 
and reliable tool that could be used in everyday clinical practice 
for assessment of health status in Serbian COPD patients. 
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